Program
gocatamig
Its studies are mostly in Small Cell Lung Carcinoma, led by Merck.
Furthest: phase 3, since Oct 26, 20264 company-led studies, 4 open or runningNext primary completion: Jan 28, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 44 open or running | phase 3since Oct 26, 2026 | Jul 6, 2020 | Jan 28, 2028phase 2 · NCT04471727 |
- Named in Merck’s own pipeline as
gocatamig (MK-6070)
, phase 2, as of Nov 2, 2026 (source).
Also a collaborator on its studies: Daiichi Sankyo.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 6, 2020First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT04471727 · 232 enrolled · United States
- Jan 13, 2025Phase 2 study in Small Cell Lung CarcinomaNCT06780137 · 327 planned · United States, Argentina, Australia and more
- Nov 10, 2025Phase 2 study in Small Cell Lung Cancer Extensive StageNCT07227597 · 170 planned · United States, Argentina, Chile and more
- Oct 26, 2026Phase 3 study in Small Cell Lung CarcinomaPhase 3 reachedNCT07908537 · 564 planned
Ahead
- Jan 28, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT04471727
- Feb 15, 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT06780137
- Nov 29, 2030Primary completion: phase 2 study in Small Cell Lung Cancer Extensive StageNCT07227597
- Dec 8, 2031Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07908537
TargetBeta
“A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) containing three humanized antibody derived binding domains: a N-terminal single chain Fv (scFv) that binds to the epsilon domain of CD3 antigen (CD3e) of the T cell receptor (TCR), a middle single dom…”NCIt, read by Claude
“A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) containing three humanized antibody derived binding domains: a N-terminal single chain Fv (scFv) that binds to the epsilon domain of CD3 antigen (CD3e) of the T cell receptor (TCR), a middle single domain”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| HLX3901 | Fosun Pharma | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07908537Small Cell Lung Carcinoma | 3 | Not yet recruiting | Dec 8, 2031 | 564 |
| NCT07227597Small Cell Lung Cancer Extensive Stage · United States, Argentina, Chile and more | 2 | Recruiting | Nov 29, 2030 | 170 |
| NCT06780137Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 2 | Recruiting | Feb 15, 2029 | 327 |
| NCT04471727Small Cell Lung Carcinoma · United States | 2 | Active, not recruiting | Jan 28, 2028 | 232 |
How it is read
Names in the registry
- “Gocatamig”, 4 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.